Toshiki Horii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Toshiki Horii has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Chika Kusano
Department of Gastroenterology Kitasato University of Medicine Kanagawa Japan
6 shared publications- Sho Suzuki
Department of Gastroenterology International University of Health and Welfare Ichikawa Hospital Chiba Japan
6 shared publications Hisatomo Ikehara
Department of Gastroenterology Kitasato University of Medicine Kanagawa Japan
4 shared publications- Hisatomo Ikehara
Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan
3 shared publications Ryoji Ichijima
Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Itabashi City, Japan
3 shared publications- Chika Kusano
Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan
2 shared publications
Latest Publications
- Open Access
- 21 March 2025
- Published by S. Karger AG in Digestion
- Vol. 106 (5) , 429-436
Is the Helicobacter pylori Stool Antigen Test with the Bioluminescent Enzyme Immunoassay Affected by Proton Pump Inhibitors?
Introduction: Proton pump inhibitors (PPIs) can lead to false-negative results in Helicobacter pylori stool antigen (HpSA) testing. A new bioluminescent enzyme immunoassay (BLEIA)-based HpSA test was introduced. This study aimed to evaluate the sensitivity of this test in patients on PPIs and compare its sensitivity with that of the enzyme immunoassay (EIA). Methods: We included patients without a history of H. pylori eradication who were diagnosed as H. pylori-positive via culture, microscopy, rapid urease tests, urea breath tests, serum H. pylori antibody tests, or HpSA tests. The sensitivity of HpSA detection was compared among patients based on their PPI intake using both BLEIA and conventional EIA. Results: Enrollment occurred from December 2020 to July 2022 across 10 facilities, with 109 patients enrolled in both the PPI and non-PPI groups. The sensitivity of BLEIA was 65.9% in the PPI group and 87.1% in the non-PPI group, showing a difference of −22.0% (95% CI: −11.0% to −32.9%) (p = 0.0003). For EIA, the sensitivity was 54.1% in the PPI group and 72.4% in the non-PPI group, with a difference of −18.3% (95% CI: −5.5% to −30.4%) (p = 0.0076). Significant differences in sensitivity were observed for both BLEIA and EIA between the PPI and non-PPI groups (p = 0.005 and p < 0.0001, respectively), with BLEIA demonstrating higher sensitivity. Conclusion: This study indicated that the sensitivity of HpSA detection using BLEIA decreased under PPI administration. Additionally, BLEIA may have higher sensitivity than EIA.
- 21 March 2025
- Published by S. Karger AG in Digestion
- Vol. 106 (5) , 429-436
Open AccessIs the Helicobacter pylori Stool Antigen Test with the Bioluminescent Enzyme Immunoassay Affected by Proton Pump Inhibitors?
Introduction: Proton pump inhibitors (PPIs) can lead to false-negative results in Helicobacter pylori stool antigen (HpSA) testing. A new bioluminescent enzyme immunoassay (BLEIA)-based HpSA test was introduced. This study aimed to evaluate the sensitivity of this test in patients on PPIs and compare its sensitivity with that of the enzyme immunoassay (EIA). Methods: We included patients without a history of H. pylori eradication who were diagnosed as H. pylori-positive via culture, microscopy, rapid urease tests, urea breath tests, serum H. pylori antibody tests, or HpSA tests. The sensitivity of HpSA detection was compared among patients based on their PPI intake using both BLEIA and conventional EIA. Results: Enrollment occurred from December 2020 to July 2022 across 10 facilities, with 109 patients enrolled in both the PPI and non-PPI groups. The sensitivity of BLEIA was 65.9% in the PPI group and 87.1% in the non-PPI group, showing a difference of −22.0% (95% CI: −11.0% to −32.9%) (p = 0.0003). For EIA, the sensitivity was 54.1% in the PPI group and 72.4% in the non-PPI group, with a difference of −18.3% (95% CI: −5.5% to −30.4%) (p = 0.0076). Significant differences in sensitivity were observed for both BLEIA and EIA between the PPI and non-PPI groups (p = 0.005 and p < 0.0001, respectively), with BLEIA demonstrating higher sensitivity. Conclusion: This study indicated that the sensitivity of HpSA detection using BLEIA decreased under PPI administration. Additionally, BLEIA may have higher sensitivity than EIA.
- Open Access
Comparison of the resection depth between endoscopic mucosal resection and underwater endoscopic mucosal resection for superficial non‐ampullary duodenal epithelial tumors: A retrospective study
Objectives: There is concern that underwater endoscopic mucosal resection (UWEMR) uses buoyancy to elevate the lesion for snare resection, resulting in a shallower resection depth than that in endoscopic mucosal resection (EMR). We aimed to compare conventional EMR and UWEMR in terms of resection depth.Methods: We retrospectively reviewed cases in which EMR or UWEMR was performed for superficial non‐ampullary duodenal epithelial tumors of ≤20 mm between April 2018 and February 2024. The endpoints were histological complete resection rate, en bloc resection rate, presence of muscularis mucosa and submucosa in the resection specimen, and submucosal index calculated from the resection specimen.Results: EMR was performed on 19 lesions and UWEMR was performed on 52 lesions. Histological complete and en bloc resection rates were not significantly different between EMR and UWEMR (57.9% and 63.5%, respectively, p = 0.78; 78.9% and 90.4%, respectively, p = 0.24). No significant differences were observed between EMR and UWEMR in the muscularis mucosa of the resected specimens (78.9% and 92.3%, respectively, p = 0.20). The presence of submucosa in resected specimens was encountered less often in EMR cases than in UWEMR cases (57.9% versus [vs.] 84.6%, p = 0.03). There were significant differences in the submucosal index in the resected specimens between EMR and UWEMR cases (median 0.15 [interquartile range 0–0.39] vs. 0.33 [0.17–0.57], p = 0.04).Conclusion: UWEMR potentially includes the submucosa within the specimen.
Open AccessComparison of the resection depth between endoscopic mucosal resection and underwater endoscopic mucosal resection for superficial non‐ampullary duodenal epithelial tumors: A retrospective study
Objectives: There is concern that underwater endoscopic mucosal resection (UWEMR) uses buoyancy to elevate the lesion for snare resection, resulting in a shallower resection depth than that in endoscopic mucosal resection (EMR). We aimed to compare conventional EMR and UWEMR in terms of resection depth.Methods: We retrospectively reviewed cases in which EMR or UWEMR was performed for superficial non‐ampullary duodenal epithelial tumors of ≤20 mm between April 2018 and February 2024. The endpoints were histological complete resection rate, en bloc resection rate, presence of muscularis mucosa and submucosa in the resection specimen, and submucosal index calculated from the resection specimen.Results: EMR was performed on 19 lesions and UWEMR was performed on 52 lesions. Histological complete and en bloc resection rates were not significantly different between EMR and UWEMR (57.9% and 63.5%, respectively, p = 0.78; 78.9% and 90.4%, respectively, p = 0.24). No significant differences were observed between EMR and UWEMR in the muscularis mucosa of the resected specimens (78.9% and 92.3%, respectively, p = 0.20). The presence of submucosa in resected specimens was encountered less often in EMR cases than in UWEMR cases (57.9% versus [vs.] 84.6%, p = 0.03). There were significant differences in the submucosal index in the resected specimens between EMR and UWEMR cases (median 0.15 [interquartile range 0–0.39] vs. 0.33 [0.17–0.57], p = 0.04).Conclusion: UWEMR potentially includes the submucosa within the specimen.
- 14 May 2024
- Published by S. Karger AG in Digestion
- Vol. 105 (4) , 291-298
Efficacy of Cricoid Pressure Application during Esophagogastroduodenoscopy in Patients with Poor Gastric Wall Extension
Introduction: Esophagogastroduodenoscopy (EGD) requires adequate air infusion. However, cases of poor gastrointestinal wall extension due to frequent eructation have been reported. Sufficient gastrointestinal wall extension can be achieved by applying cricoid pressure during EGD. Herein, we evaluated the frequency of cases with poor gastrointestinal wall extension and the efficacy and safety of applying cricoid pressure during EGD. Methods: This interventional study included patients who underwent EGD between January 2020 and December 2020 at the JA Akita Koseiren Yuri Kumiai General Hospital. Cases wherein folds of the greater curvature of the upper gastric body were not sufficiently extended during EGD were considered to have poor gastrointestinal wall extension. In such cases, air infusion was performed while applying cricoid pressure. This procedure was considered effective when gastric wall extension was achieved. Results: A total of 2,000 patients were enrolled and underwent upper gastrointestinal endoscopy; however, five were excluded because of upper gastrointestinal tract stenosis. Observation of gastric wall extension of the greater curvature in the upper gastric body with normal air insufflation was difficult in 113 (5.7%) cases. Applying cricoid pressure was effective in 93 (82.3%) patients with poor gastric wall extension. Sufficient gastric wall extension was achieved within an average of 12.8 s in cases where cricoid pressure application was effective. No adverse events were associated with cricoid pressure application. Conclusions: Cricoid pressure application for patients with poor gastric wall extension during EGD is useful for ensuring a sufficient field of view during observation of the gastric body.
- 14 May 2024
- Published by S. Karger AG in Digestion
- Vol. 105 (4) , 291-298
Efficacy of Cricoid Pressure Application during Esophagogastroduodenoscopy in Patients with Poor Gastric Wall Extension
Introduction: Esophagogastroduodenoscopy (EGD) requires adequate air infusion. However, cases of poor gastrointestinal wall extension due to frequent eructation have been reported. Sufficient gastrointestinal wall extension can be achieved by applying cricoid pressure during EGD. Herein, we evaluated the frequency of cases with poor gastrointestinal wall extension and the efficacy and safety of applying cricoid pressure during EGD. Methods: This interventional study included patients who underwent EGD between January 2020 and December 2020 at the JA Akita Koseiren Yuri Kumiai General Hospital. Cases wherein folds of the greater curvature of the upper gastric body were not sufficiently extended during EGD were considered to have poor gastrointestinal wall extension. In such cases, air infusion was performed while applying cricoid pressure. This procedure was considered effective when gastric wall extension was achieved. Results: A total of 2,000 patients were enrolled and underwent upper gastrointestinal endoscopy; however, five were excluded because of upper gastrointestinal tract stenosis. Observation of gastric wall extension of the greater curvature in the upper gastric body with normal air insufflation was difficult in 113 (5.7%) cases. Applying cricoid pressure was effective in 93 (82.3%) patients with poor gastric wall extension. Sufficient gastric wall extension was achieved within an average of 12.8 s in cases where cricoid pressure application was effective. No adverse events were associated with cricoid pressure application. Conclusions: Cricoid pressure application for patients with poor gastric wall extension during EGD is useful for ensuring a sufficient field of view during observation of the gastric body.
- Open Access
Monitoring of leucine‐rich alpha‐2‐glycoprotein and assessment by small bowel capsule endoscopy are prognostic for Crohn's disease patients
Background and Aim: Endoscopy is important to determine the effectiveness of treatment for Crohn's disease (CD), but searching the entire small intestine is difficult. Thus, we investigated the usefulness of leucine‐rich alpha‐2 glycoprotein (LRG), a new biomarker for predicting mucosal activity, in evaluating the activity of CD small intestinal lesions. This will further determine whether the results of small bowel capsule endoscopy (SBCE) affect the prognosis of patients with CD.Methods: A total of 114 patients with CD who underwent SBCE were included. We analyzed the correlation between LRG and Capsule Endoscopy Crohn's Disease Activity Index (CECDAI). The cutoff value of LRG to achieve mucosal healing was calculated using the receiver operating characteristic curve. Then, we compared the presence or absence of intervention and the relapse rate of patients who could not achieve mucosal healing.Results: The CECDAI correlated with LRG. The calculated LRG value for achieving mucosal healing was ≤11.9. Ninety‐one patients were in clinical remission at the time of SBCE. During the follow‐up period, 17 patients relapsed. As a result of SBCE, when no treatment intervention was performed in the case of CECDAI ≥3.5, the relapse rate was significantly higher than when CECDAI <3.5 or intervention was performed in the case of CECDAI ≥3.5.Conclusions: The results reveal that LRG correlates with the activity of the entire small intestine and that SBCE assessment and therapeutic intervention can influence patient prognosis.
Open AccessMonitoring of leucine‐rich alpha‐2‐glycoprotein and assessment by small bowel capsule endoscopy are prognostic for Crohn's disease patients
Background and Aim: Endoscopy is important to determine the effectiveness of treatment for Crohn's disease (CD), but searching the entire small intestine is difficult. Thus, we investigated the usefulness of leucine‐rich alpha‐2 glycoprotein (LRG), a new biomarker for predicting mucosal activity, in evaluating the activity of CD small intestinal lesions. This will further determine whether the results of small bowel capsule endoscopy (SBCE) affect the prognosis of patients with CD.Methods: A total of 114 patients with CD who underwent SBCE were included. We analyzed the correlation between LRG and Capsule Endoscopy Crohn's Disease Activity Index (CECDAI). The cutoff value of LRG to achieve mucosal healing was calculated using the receiver operating characteristic curve. Then, we compared the presence or absence of intervention and the relapse rate of patients who could not achieve mucosal healing.Results: The CECDAI correlated with LRG. The calculated LRG value for achieving mucosal healing was ≤11.9. Ninety‐one patients were in clinical remission at the time of SBCE. During the follow‐up period, 17 patients relapsed. As a result of SBCE, when no treatment intervention was performed in the case of CECDAI ≥3.5, the relapse rate was significantly higher than when CECDAI <3.5 or intervention was performed in the case of CECDAI ≥3.5.Conclusions: The results reveal that LRG correlates with the activity of the entire small intestine and that SBCE assessment and therapeutic intervention can influence patient prognosis.
- 10 January 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (5) , 752-760
Comparison of complete resection rates in cold snare polypectomy using two different wire diameter snares: A randomized controlled study
Background and Aim: Cold snare polypectomy (CSP) is a standard treatment for small colorectal polyps. This study examined the effect of different snare wire diameters on complete histological resection rate, resection depth, and CSP safety.Methods: This randomized controlled trial was conducted at two institutions between June 2019 and March 2021. Eligible colorectal polyps (≤10 mm) were randomly assigned in a 1:1 ratio to receive either CSP with a conventional snare made of normal‐diameter wire (0.40 mm) or CSP with a dedicated snare made of thin wire (0.23 mm). The primary endpoint was the complete resection rate determined on histological assessment of the resected specimen.Results: In total, 254 lesions in 152 patients were included, with 128 and 126 lesions assigned to the normal‐diameter wire snare group and the thin‐wire snare group, respectively. No significant differences were observed in patient characteristics between the two groups. The histological complete resection rate was significantly higher in the thin‐wire snare group than in the normal‐diameter wire snare group (70.0% vs 81.0%, P = 0.04). The normal‐diameter wire snare group had significantly more cases of unclear horizontal margin evaluation than the thin‐wire snare group (28.1% vs 15.9%, P = 0.02). No significant differences were observed between the two groups in the muscularis mucosa and submucosa of the resected specimens or the thickness of the submucosa in the resected specimens.Conclusions: CSP with a dedicated thin‐wire snare provides more specimens that can be evaluated at the horizontal end and increases the histological complete resection rate.
- 10 January 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (5) , 752-760
Comparison of complete resection rates in cold snare polypectomy using two different wire diameter snares: A randomized controlled study
Background and Aim: Cold snare polypectomy (CSP) is a standard treatment for small colorectal polyps. This study examined the effect of different snare wire diameters on complete histological resection rate, resection depth, and CSP safety.Methods: This randomized controlled trial was conducted at two institutions between June 2019 and March 2021. Eligible colorectal polyps (≤10 mm) were randomly assigned in a 1:1 ratio to receive either CSP with a conventional snare made of normal‐diameter wire (0.40 mm) or CSP with a dedicated snare made of thin wire (0.23 mm). The primary endpoint was the complete resection rate determined on histological assessment of the resected specimen.Results: In total, 254 lesions in 152 patients were included, with 128 and 126 lesions assigned to the normal‐diameter wire snare group and the thin‐wire snare group, respectively. No significant differences were observed in patient characteristics between the two groups. The histological complete resection rate was significantly higher in the thin‐wire snare group than in the normal‐diameter wire snare group (70.0% vs 81.0%, P = 0.04). The normal‐diameter wire snare group had significantly more cases of unclear horizontal margin evaluation than the thin‐wire snare group (28.1% vs 15.9%, P = 0.02). No significant differences were observed between the two groups in the muscularis mucosa and submucosa of the resected specimens or the thickness of the submucosa in the resected specimens.Conclusions: CSP with a dedicated thin‐wire snare provides more specimens that can be evaluated at the horizontal end and increases the histological complete resection rate.
- Open Access
- 18 October 2021
- Published by S. Karger AG in Digestion
- Vol. 103 (1) , 62-68
The Ideal Helicobacter pylori Treatment for the Present and the Future
Background: Helicobacter pylori eradication treatments are widely performed to improve gastric mucosal inflammation, promote ulcer healing, and reduce the incidence of gastric cancer. However, there are several issues associated with H. pylori eradication treatment. First, various treatment regimens are currently used worldwide, and the standard treatment varies with region and country. Second, the antimicrobial resistance of H. pylori is increasing due to indiscriminate antibiotic use. Finally, gut microbiota dysbiosis is potentially induced by H. pylori treatment. Summary: Based on current international guidelines and a network meta-analysis comparing the effects of various treatment regimens, nonbismuth quadruple therapies for 10–14 days and vonoprazan-based triple therapy for 7 days are the currently recommended H. pylori treatment regimens. These regimens show good eradication rates of approximately 90%, even in areas where antimicrobial-resistant strains are highly prevalent. However, these regimens still have inherent drawbacks that may promote further increases in antimicrobial resistance and induce gut microbiota dysbiosis because of the empiric use of multiple antibiotics. Key Message: The ideal concept for the present and future H. pylori eradication treatment involves “a simple, cost-effective strategy that fosters compliance without having a negative impact on the gut microbiota or contributing to future antimicrobial resistance.” One interesting possibility that may fulfill this concept is a dual therapy involving vonoprazan and amoxicillin. This is the simplest treatment regimen that provides acceptable eradication rates, improves safety and tolerability, and minimizes the potential for increasing antimicrobial resistance or causing gut microbiota dysbiosis.
- 18 October 2021
- Published by S. Karger AG in Digestion
- Vol. 103 (1) , 62-68
Open AccessThe Ideal Helicobacter pylori Treatment for the Present and the Future
Background: Helicobacter pylori eradication treatments are widely performed to improve gastric mucosal inflammation, promote ulcer healing, and reduce the incidence of gastric cancer. However, there are several issues associated with H. pylori eradication treatment. First, various treatment regimens are currently used worldwide, and the standard treatment varies with region and country. Second, the antimicrobial resistance of H. pylori is increasing due to indiscriminate antibiotic use. Finally, gut microbiota dysbiosis is potentially induced by H. pylori treatment. Summary: Based on current international guidelines and a network meta-analysis comparing the effects of various treatment regimens, nonbismuth quadruple therapies for 10–14 days and vonoprazan-based triple therapy for 7 days are the currently recommended H. pylori treatment regimens. These regimens show good eradication rates of approximately 90%, even in areas where antimicrobial-resistant strains are highly prevalent. However, these regimens still have inherent drawbacks that may promote further increases in antimicrobial resistance and induce gut microbiota dysbiosis because of the empiric use of multiple antibiotics. Key Message: The ideal concept for the present and future H. pylori eradication treatment involves “a simple, cost-effective strategy that fosters compliance without having a negative impact on the gut microbiota or contributing to future antimicrobial resistance.” One interesting possibility that may fulfill this concept is a dual therapy involving vonoprazan and amoxicillin. This is the simplest treatment regimen that provides acceptable eradication rates, improves safety and tolerability, and minimizes the potential for increasing antimicrobial resistance or causing gut microbiota dysbiosis.
- 6 September 2021
- Published by Wiley in Helicobacter
- Vol. 26 (6) , e12851
Long term impact of vonoprazan‐based Helicobacter pylori treatment on gut microbiota and its relation to post‐treatment body weight changes
Background: Vonoprazan‐based Helicobacter pylori (H. pylori) treatment is highly effective in eradicating the target bacteria; however, its post‐1‐year impact on gut microbiota is unknown. This study evaluated the impact of vonoprazan‐based H. pylori therapy on gut microbiota 1‐year post‐therapy and investigated the relationship between body weight changes and post‐therapy gut microbiota perturbations.Materials and Methods: Between March and May 2019, 43 patients with H. pylori infections received either vonoprazan/amoxicillin (VA) or vonoprazan/amoxicillin/clarithromycin (VAC) therapy. Fecal samples were collected prior to treatment and 1 year after treatment. The alpha and beta diversities and the bacterial taxa composition ratios were determined using polymerase chain reaction amplification of the V3–V4 region of the 16S ribosomal RNA gene. The correlation between body weight changes and relative abundances of genera post‐therapy was also analyzed.Results: Among the 43 patients, 18 received VA therapy and 21 received VAC therapy. One year after treatment, the alpha diversity was significantly higher in both the treatment groups (p < .001, using observed operational taxonomic units and Chao1 index), and beta diversity was significantly different in both the groups (p = .001, using unweighted UniFrac distance) compared with baseline findings. Significant positive correlations were found between body weight changes and the relative abundances of Coprococcus spp. (p = .037) and Odoribacter spp. (p = .022) post‐therapy.Conclusion: Vonoprazan‐based H. pylori therapies are associated with long‐term impacts on gut microbiota, including effects on bacterial species richness, and potentially affect metabolism by altering the microbiota. Trial registration number: UMIN000040025.
- 6 September 2021
- Published by Wiley in Helicobacter
- Vol. 26 (6) , e12851
Long term impact of vonoprazan‐based Helicobacter pylori treatment on gut microbiota and its relation to post‐treatment body weight changes
Background: Vonoprazan‐based Helicobacter pylori (H. pylori) treatment is highly effective in eradicating the target bacteria; however, its post‐1‐year impact on gut microbiota is unknown. This study evaluated the impact of vonoprazan‐based H. pylori therapy on gut microbiota 1‐year post‐therapy and investigated the relationship between body weight changes and post‐therapy gut microbiota perturbations.Materials and Methods: Between March and May 2019, 43 patients with H. pylori infections received either vonoprazan/amoxicillin (VA) or vonoprazan/amoxicillin/clarithromycin (VAC) therapy. Fecal samples were collected prior to treatment and 1 year after treatment. The alpha and beta diversities and the bacterial taxa composition ratios were determined using polymerase chain reaction amplification of the V3–V4 region of the 16S ribosomal RNA gene. The correlation between body weight changes and relative abundances of genera post‐therapy was also analyzed.Results: Among the 43 patients, 18 received VA therapy and 21 received VAC therapy. One year after treatment, the alpha diversity was significantly higher in both the treatment groups (p < .001, using observed operational taxonomic units and Chao1 index), and beta diversity was significantly different in both the groups (p = .001, using unweighted UniFrac distance) compared with baseline findings. Significant positive correlations were found between body weight changes and the relative abundances of Coprococcus spp. (p = .037) and Odoribacter spp. (p = .022) post‐therapy.Conclusion: Vonoprazan‐based H. pylori therapies are associated with long‐term impacts on gut microbiota, including effects on bacterial species richness, and potentially affect metabolism by altering the microbiota. Trial registration number: UMIN000040025.
- 9 June 2021
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 36 (12) , 3314-3321
Lower impact of vonoprazan–amoxicillin dual therapy on gut microbiota forHelicobacter pylorieradication
Background and Aim: Helicobacter pylorieradication can disrupt the gut microbiome. Here, we investigated the short‐term impact of minimum antibiotic treatment—a 7‐day vonoprazan and low‐dose amoxicillin regimen (VA‐dual therapy)—on gut microbiota and compared it with that of vonoprazan‐based triple therapy (VAC‐triple therapy).Methods: Fifty‐nine patients withH. pyloriinfection were recruited (UMIN000034140) from March to May 2019 and randomly assigned to the VAC‐triple therapy or VA‐dual therapy groups, according to the first‐lineH. pyloritreatment received. Fecal samples were collected before treatment initiation and 1 and 8 weeks after eradication therapy completion. The composition ratios of the bacterial taxa and the alpha and beta diversities were evaluated in both groups via polymerase chain reaction amplification of the V3–V4 region of the 16S rRNA gene and sequencing using the MiSeq system.Results: Nineteen patients were assigned to the VA‐dual group and 24 to the VAC‐triple group. Compared with baseline, the alpha diversity reduced significantly 1 and 8 weeks after VAC‐triple therapy. However, for VA‐dual therapy, the alpha diversities at 1 and 8 weeks after the treatment did not change significantly compared with those at baseline. Additionally, the beta diversity differed significantly between baseline and 1 and 8 weeks after VAC‐triple therapy. VAC‐triple therapy led to significant alteration in the relative abundance of Actinobacteria at the phylum level andCollinsella,Blautia, andStreptococcusat the genus level.Conclusions: Compared with VAC‐triple therapy, VA‐dual therapy induced minimal changes in the diversity and relative abundance of gut microbiota.
- 9 June 2021
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 36 (12) , 3314-3321
Lower impact of vonoprazan–amoxicillin dual therapy on gut microbiota forHelicobacter pylorieradication
Background and Aim: Helicobacter pylorieradication can disrupt the gut microbiome. Here, we investigated the short‐term impact of minimum antibiotic treatment—a 7‐day vonoprazan and low‐dose amoxicillin regimen (VA‐dual therapy)—on gut microbiota and compared it with that of vonoprazan‐based triple therapy (VAC‐triple therapy).Methods: Fifty‐nine patients withH. pyloriinfection were recruited (UMIN000034140) from March to May 2019 and randomly assigned to the VAC‐triple therapy or VA‐dual therapy groups, according to the first‐lineH. pyloritreatment received. Fecal samples were collected before treatment initiation and 1 and 8 weeks after eradication therapy completion. The composition ratios of the bacterial taxa and the alpha and beta diversities were evaluated in both groups via polymerase chain reaction amplification of the V3–V4 region of the 16S rRNA gene and sequencing using the MiSeq system.Results: Nineteen patients were assigned to the VA‐dual group and 24 to the VAC‐triple group. Compared with baseline, the alpha diversity reduced significantly 1 and 8 weeks after VAC‐triple therapy. However, for VA‐dual therapy, the alpha diversities at 1 and 8 weeks after the treatment did not change significantly compared with those at baseline. Additionally, the beta diversity differed significantly between baseline and 1 and 8 weeks after VAC‐triple therapy. VAC‐triple therapy led to significant alteration in the relative abundance of Actinobacteria at the phylum level andCollinsella,Blautia, andStreptococcusat the genus level.Conclusions: Compared with VAC‐triple therapy, VA‐dual therapy induced minimal changes in the diversity and relative abundance of gut microbiota.
- 10 September 2019
- Published by S. Karger AG in Digestion
- Vol. 102 (2) , 155-160
The Accuracy of the Serum Antibody Test for Helicobacter pylori Infection among Junior High School Students
Objective: Recently, screening for Helicobacter pylori infection has been performed among children in Japan as a prevention strategy for gastric cancer. However, the diagnostic accuracy of the serum antibody test, using the ELISA-kit, for screening in children has not been confirmed, and it is unknown whether the cutoff value used for adults is appropriate for children. The aim of this study was to evaluate the accuracy of the serum antibody test for H. pylori infection for the mass screening of junior high school students in Japan. Subjects and Methods: H. pylori infection testing and eradication therapy in junior high schools began in the 2015 fiscal year for students in Yurihonjo and Nikaho cities, located in the Akita prefecture. The data of 410 students who underwent both stool antigen tests (SATs) and serum antibody test, between 2016 and 2018, were used for analysis. Students who had positive results on the SATs test were diagnosed with H. pylori infection. Results: The rate of H. pylori infection was 3.7% (15/410). The optimal cutoff of serum antibody for children was identified to be 5.4 U/mL, with this cutoff having an area under the curve of 0.94 (95% CI 0.83–1.00), specificity of 99.5% (95% CI 98.2–99.9) and sensitivity of 93.3% (95% CI 68.1–99.8), which was wide because of the small sample size. Conclusion: The accuracy of the serum antibody test may be enough for practical use in children 13–14 years old
- 10 September 2019
- Published by S. Karger AG in Digestion
- Vol. 102 (2) , 155-160
The Accuracy of the Serum Antibody Test for Helicobacter pylori Infection among Junior High School Students
Objective: Recently, screening for Helicobacter pylori infection has been performed among children in Japan as a prevention strategy for gastric cancer. However, the diagnostic accuracy of the serum antibody test, using the ELISA-kit, for screening in children has not been confirmed, and it is unknown whether the cutoff value used for adults is appropriate for children. The aim of this study was to evaluate the accuracy of the serum antibody test for H. pylori infection for the mass screening of junior high school students in Japan. Subjects and Methods: H. pylori infection testing and eradication therapy in junior high schools began in the 2015 fiscal year for students in Yurihonjo and Nikaho cities, located in the Akita prefecture. The data of 410 students who underwent both stool antigen tests (SATs) and serum antibody test, between 2016 and 2018, were used for analysis. Students who had positive results on the SATs test were diagnosed with H. pylori infection. Results: The rate of H. pylori infection was 3.7% (15/410). The optimal cutoff of serum antibody for children was identified to be 5.4 U/mL, with this cutoff having an area under the curve of 0.94 (95% CI 0.83–1.00), specificity of 99.5% (95% CI 98.2–99.9) and sensitivity of 93.3% (95% CI 68.1–99.8), which was wide because of the small sample size. Conclusion: The accuracy of the serum antibody test may be enough for practical use in children 13–14 years old